IDXG - Interpace Diagnostics Group, Inc.
| Previous Close | 0.7297 |
| Open | 0.7120 |
| Bid | 0.7385 x 3200 |
| Ask | 0.7493 x 800 |
| Day's Range | 0.7000 - 0.7500 |
| 52 Week Range | 0.6700 - 1.7800 |
| Volume | 296,991 |
| Avg. Volume | 291,709 |
| Market Cap | 27.985M |
| Beta (3Y Monthly) | 2.24 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4190 |
| Earnings Date | Aug 14, 2017 - Aug 18, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.84 |
- Thomson Reuters StreetEvents•5 days ago
Edited Transcript of IDXG earnings conference call or presentation 13-May-19 8:30pm GMT
Q1 2019 Interpace Diagnostics Group Inc Earnings Call
- GlobeNewswire•11 days ago
Interpace Diagnostics Reports First Quarter 2019 Financial Results and Provides Business Update
Quarterly Revenue Grew to $6.0 Million, a 25% Increase Year-over-Year Annual 2019 Revenue Guidance of $27 to $28 Million, a 25% Increase Conference Call and Webcast.
- GlobeNewswire•15 days ago
Interpace Diagnostics BarreGEN® Data to be Presented at Digestive Disease Week
PARSIPPANY, NJ, May 09, 2019 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (IDXG) announced today that data from an independent study, which showed that BarreGEN® performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to visible appearance of advanced histology, will be presented at the annual Digestive Disease Week® (“DDW”). The meeting will be held in San Diego, CA on May 18-21, 2019, and is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery.
- GlobeNewswire•18 days ago
Interpace Diagnostics to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on Monday, May 13, 2019
Interpace Diagnostics Group, Inc., (IDXG:NASDAQ) announced today that it will report its first quarter 2019 financial results after the close of market on Monday, May 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Company’s financial results and provide a general business update. A webcast replay will be available on the company’s website (www.interpacediagnostics.com) approximately two hours following completion of the call and will be archived on the company’s website for 90 days.
- GlobeNewswire•23 days ago
Interpace Diagnostics Announces Publication of Important New Data on Thyroid Test Performance
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”) announced today that data from its thyroid registry has been published in the peer reviewed publication Diagnostic Cytopathology in a paper called “Clinical impact of testing for mutation and microRNA’s in thyroid nodules.” The new data from over 300 samples was compiled from a two-year, real-world, retrospective study and highlighted the clinical utility of Interpace’s ThyGenX® thyroid oncogene panel in combination with ThyraMIR®, its micro-RNA classifier. Importantly, the study also showed that surgical decisions made with our combination thyroid tests were appropriately aligned with risk of malignancy over multiple years of clinical follow-up, which is consistent with a combination test that effectively rules-in and rules-out higher risk of malignancy.
- Simply Wall St.•25 days ago
Interpace Diagnostics Group, Inc.'s (NASDAQ:IDXG) Shift From Loss To Profit
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Interpace Diagnostics Group, Inc.'s (NASDAQ:IDXG): Interpace Diagnostics Group, Inc. develops a...
- GlobeNewswire•29 days ago
Interpace Diagnostics Labs Receive College of American Pathology (CAP) Accreditation
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has received the College of American Pathologists (“CAP”) accreditation for its Pittsburgh, Pennsylvania and New Haven, Connecticut laboratories. Only after the Clinical Laboratory Improvement Amendments of 1988 (“CLIA”) designation has been received can a laboratory apply for the more rigorous CAP accreditation.
- GlobeNewswire•last month
Interpace Diagnostics Announces New York State Approval
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has received approval to launch ThyraMIR® diagnostic testing on formalin-fixed, paraffin-embedded (“FFPE”) tissue samples from thyroid nodules from the State of New York. ThyraMIR® is now the only molecular test approved to be used on indeterminate thyroid nodule samples presented via fine needle aspirates in RNA Retain®, cytology slides, and FFPE fixation in the State of New York. In combination with the previous New York State approval of the Company’s next-generation thyroid product, ThyGeNEXTÒ, physicians and patients now have increased access to Interpace’s thyroid product suite across a wide spectrum of specimen types providing a single point of access for molecular testing.
- GlobeNewswire•2 months ago
Interpace Diagnostics Announces New Coverage of Thyroid Testing by Medica
Interpace Diagnostics Group, Inc. (IDXG) announced today that Medica, one of the largest health plans spanning numerous states throughout the Midwest, has extended coverage of both ThyGeNEXT™ and ThyraMIR® to its 1.3 million covered lives. Physicians across Medica’s entire network will now be able to utilize Interpace’s thyroid products to assess indeterminate nodules providing patients with added diagnostic options. Since ThyGenX was launched in 2014, Interpace has conducted over 25,000 thyroid tests for over 700 physicians and hospitals nationwide.
- GuruFocus.com•2 months ago
Interpace Diagnostics Group Inc (IDXG) Files 10-K for the Fiscal Year Ended on December 31, 2018
Interpace Diagnostics Group Inc is engaged in developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for diagnosis and management. Interpace Diagnostics Group Inc had annual average EBITDA growth of 6.90% over the past five years. Warning! GuruFocus has detected 2 Warning Signs with IDXG.
- Thomson Reuters StreetEvents•2 months ago
Edited Transcript of IDXG earnings conference call or presentation 19-Mar-19 8:30pm GMT
Q4 2018 Interpace Diagnostics Group Inc Earnings Call
- GlobeNewswire•2 months ago
Interpace Diagnostics Group Reports Full Year and Fourth Quarter 2018 Financial Results
Business Progress and Recent Accomplishments Highlighted and Discussed Further on Conference Call PARSIPPANY, NJ, March 19, 2019 -- Interpace Diagnostics Group, Inc..
- Simply Wall St.•3 months ago
What Kind Of Shareholder Owns Most Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Stock?
If you want to know who really controls Interpace Diagnostics Group, Inc. (NASDAQ:IDXG), then you'll have to look at the makeup of its share registry. Institutions often own shares inRead More...
- GlobeNewswire•3 months ago
Interpace Diagnostics Receives Regional Award as 2018 Top Life Sciences Company
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or “the Company”) announced today that the Pittsburgh Business Times has designated Interpace Diagnostics as its 2018 Top Life Sciences Company award winner. The Pittsburgh location serves as the Company’s largest laboratory and provides a wide variety of services including cytology, molecular testing, and pathology. All four of Interpace’s DNA-based testing products along with their clinical testing are performed at the Pittsburgh lab.
- GlobeNewswire•3 months ago
Interpace Diagnostics Announces Preliminary 2018 Revenues
Interpace to Host Fourth Quarter and Full Year 2018 Results Conference Call/Webcast PARSIPPANY, NJ, Feb. 28, 2019 -- Interpace Diagnostics Group, Inc. (NASDAQ: IDXG).
- GlobeNewswire•3 months ago
Interpace Diagnostics Announces First Independent Publication Demonstrating Clinical Utility of BarreGEN®
Interpace Diagnostics Group, Inc. (IDXG) announced today that BMJ Open Gastroenterology, an on-line, peer-reviewed, open access gastroenterology journal dedicated to publishing high-quality medical research from all disciplines and therapeutic areas of gastroenterology, has provided the first independent evidence that BarreGEN®, the Company’s lead pipeline product, performed effectively as a biomarker tool for predicting risk of developing more advanced stages of disease prior to the visible appearance of advanced histology. This is the first publication resulting from work related to the Company’s ongoing Clinical Experience Program (CEP) under which several sites across the country are using BarreGEN to provide input on its clinical utility in a real-world setting.
- GlobeNewswire•4 months ago
Interpace Diagnostics to Attend BIO CEO & Investor Conference in New York City
Interpace Diagnostics Group (IDXG) today announced the Company will attend the 21st BIO CEO & Investor Conference being held in New York, NY at the New York Marriott Marquis on February 11th & 12th, 2019. The Company will host one-on-one meetings through the BIO CEO & Investor Conference, which is one of the largest, unbiased forums of institutional investors, industry analysts, and biotechnology executives. Conference attendees can request meetings through the One-on-One Partnering platform, while non-attendees can send meeting requests to Joe Green or Wiktoria O’Hare at Edison Advisors.
- GlobeNewswire•4 months ago
Interpace Diagnostics Announces Closing of $7.0 Million Public Offering of Common Stock
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”) today announced the closing of its previously announced underwritten public offering of 9,333,334 shares of its common stock at a public offering price of $0.75 per share. Interpace has also granted the underwriter a 30-day option to purchase up to an additional 1,400,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. Interpace intends to use the net proceeds of the offering for working capital, capital expenditures, business development and research and development expenditures, and acquisition of new technologies and businesses.
- GlobeNewswire•4 months ago
Interpace Diagnostics Announces Pricing of $7.0 Million Public Offering of Common Stock
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”) today announced the pricing of an underwritten public offering of 9,333,334 shares of its common stock at a public offering price of $0.75 per share, less underwriting discounts and commissions. Interpace also granted the underwriter a 30-day option to purchase up to an additional 1,400,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions. Interpace expects to receive aggregate gross proceeds of approximately $7 million from the offering, assuming no exercise of the underwriter’s option to purchase additional shares.
- GlobeNewswire•4 months ago
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
Interpace Diagnostics Group, Inc. (IDXG) (“Interpace” or the “Company”) announced today that it intends to offer and sell shares of its common stock in a registered underwritten public offering. In addition, Interpace also intends to grant the underwriter a 30-day option to purchase additional shares of its common stock equal to 15% of the shares to be sold in the offering to cover over-allotments, if any. Interpace intends to use the net proceeds of the offering for working capital, capital expenditures, business development and research and development expenditures, and acquisition of new technologies and businesses.
- GlobeNewswire•4 months ago
Interpace Diagnostics to Present at the Fifteenth Annual NobleCon
Interpace Diagnostics Group (IDXG) today announced that Jack Stover, Chief Executive Officer, will present at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida - on Tuesday, January 29th at 1:30 pm Eastern Standard Time in Studio 1. A high-definition, video webcast of the presentation will be available the following day on the Company's website (www.interpacediagnostics.com), and as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website: www.nobleconference.com and on the new investor portal created by Noble called Channelchek: www.channelchek.com. The webcast will be archived on the company's website, the NobleCon website and on Channelchek.com for 90 days following the event.
- GlobeNewswire•4 months ago
Interpace Diagnostics Announces Further Expansion of Thyroid Business
Interpace Diagnostics Group, Inc. (IDXG) announced today that it has finalized the validation of its third specimen type for its molecular thyroid tests ThyGeNEX™ and ThyraMIR®. Interpace has expanded its services again to now also process specimens prepared in formalin fixed, paraffin-embedded (FFPE) samples. The Company initiated a partnering arrangement with the Dianon Systems Inc. division of LabCorp (LH) and certain regional labs to provide customers with a one-stop service for molecular testing for their indeterminate thyroid nodules.
- Simply Wall St.•4 months ago
Is Interpace Diagnostics Group, Inc.’s (NASDAQ:IDXG) CEO Paid Enough Relative To Peers?
In 2016 Jack Stover was appointed CEO of Interpace Diagnostics Group, Inc. (NASDAQ:IDXG). First, this article will compare CEO compensation with compensation at similar sized companies. After that, we will Read More...
- GlobeNewswire•4 months ago
Interpace Diagnostics Enters into Agreement with University of Maryland Medical System
Interpace Diagnostics Group (IDXG) has entered in to an Agreement with the University of Maryland Medical System (UMMS), which will provide physicians access to ThyGeNEXT™, ThyraMIR®, and PancraGEN® across the entire UMMS network. Physicians can utilize ThyGeNEXT™ and ThyraMIR® to assess indeterminate thyroid nodules and PancraGEN® for indeterminate pancreatic cysts and solid lesions. The UMMS network is a university-based regional health care system focused on serving the health care needs of the State of Maryland.
- GlobeNewswire•5 months ago
Interpace Diagnostics Ranked as Top 10 Bioinformatics Solutions Provider
Interpace Diagnostics Group, Inc. (IDXG) announced today that CIO Applications, a publication focused on providing professionals with information on the most comprehensive collection of technology trends, has once again recognized Interpace Diagnostics as a top bioinformatics solutions company. This year CIO Applications ranked Interpace as a Top 10 Company for providing bioinformatics solutions through the Company’s extensive database of molecular testing results. In 2017, Interpace was recognized as a Top 20 Bioinformatics Solutions Provider.
